Shanghai Junshi Biosciences Co., Ltd.* disclosed its 2025 third quarter results. According to the announcement, operating income reached approximately RMB1.81 billion for the first three quarters of 2025, marking a 42.06% year-on-year increase. The reported net loss attributable to shareholders stood at around RMB596 million, representing a narrower loss than the same period last year.

The increase in income is primarily attributed to stronger sales of commercialized drugs. Toripalimab (TUOYI®/LOQTORZI®, product code JS001) recorded approximately RMB1.50 billion in domestic sales, up by about 40% year-on-year. In parallel, the company continued its “Action Plan for Enhancing Quality and Efficiency,” reducing overall expenses and focusing resources, which contributed to the decline in net loss.

During the reporting period, research and development spending totaled roughly RMB982 million. Toripalimab was accepted for supplemental new drug application as a first-line treatment of HER2-expressing urothelial carcinoma, bringing the product’s total approved indications in Chinese mainland to 12, with 10 already included in the National Reimbursement Drug List. Internationally, toripalimab has been approved in over 40 countries and regions.

Other pipeline highlights included the U.S. Food and Drug Administration’s approval for an investigational new drug application for a phase II/III clinical study of JS207 (a PD-1/VEGF bispecific antibody), and a phase III trial success for JS005 (an IL-17A monoclonal antibody) in moderate to severe plaque psoriasis. The company’s cash and bank balances plus financial assets for trading amounted to RMB3.27 billion as of the end of the reporting period, reflecting adequate funding for ongoing operations and research progress.